Gustavo A. Rosario Benitez

Array ( [id] => 13093367 [patent_doc_number] => 10066015 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-09-04 [patent_title] => CD3 binding domains [patent_app_type] => utility [patent_app_number] => 14/820462 [patent_app_country] => US [patent_app_date] => 2015-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 7 [patent_no_of_words] => 6927 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 125 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14820462 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10729859 [patent_doc_number] => 20160076009 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-17 [patent_title] => 'ANTIGEN BINDING MOLECULES WITH INCREASED Fc RECEPTOR BINDING AFFINITY AND EFFECTOR FUNCTION' [patent_app_type] => utility [patent_app_number] => 14/815583 [patent_app_country] => US [patent_app_date] => 2015-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 30869 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14815583 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10729645 [patent_doc_number] => 20160075794 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-17 [patent_title] => 'ANTIGEN BINDING MOLECULES WITH INCREASED Fc RECEPTOR BINDING AFFINITY AND EFFECTOR FUNCTION' [patent_app_type] => utility [patent_app_number] => 14/815604 [patent_app_country] => US [patent_app_date] => 2015-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 30865 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14815604 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10729644 [patent_doc_number] => 20160075793 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-17 [patent_title] => 'ANTIGEN BINDING MOLECULES WITH INCREASED Fc RECEPTOR BINDING AFFINITY AND EFFECTOR FUNCTION' [patent_app_type] => utility [patent_app_number] => 14/815562 [patent_app_country] => US [patent_app_date] => 2015-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 30869 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14815562 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10699433 [patent_doc_number] => 20160045580 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-18 [patent_title] => 'IDENTIFICATION OF CD8+ T CELLS THAT ARE CD161HI AND/OR IL18R(ALPHA)HI AND HAVE RAPID DRUG EFFLUX CAPACITY' [patent_app_type] => utility [patent_app_number] => 14/810286 [patent_app_country] => US [patent_app_date] => 2015-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 13268 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14810286 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10980012 [patent_doc_number] => 20160176957 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-23 [patent_title] => 'Use of TNFalpha Inhibitor' [patent_app_type] => utility [patent_app_number] => 14/809828 [patent_app_country] => US [patent_app_date] => 2015-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 23896 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14809828 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10980012 [patent_doc_number] => 20160176957 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-23 [patent_title] => 'Use of TNFalpha Inhibitor' [patent_app_type] => utility [patent_app_number] => 14/809828 [patent_app_country] => US [patent_app_date] => 2015-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 23896 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14809828 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10997456 [patent_doc_number] => 20160194399 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-07 [patent_title] => 'ANTI-CD3 ANTIBODIES, ACTIVATABLE ANTI-CD3 ANTIBODIES, MULTISPECIFIC ANTI-CD3 ANTIBODIES, MULTISPECIFIC ACTIVATABLE ANTI-CD3 ANTIBODIES, AND METHODS OF USING THE SAME' [patent_app_type] => utility [patent_app_number] => 14/808711 [patent_app_country] => US [patent_app_date] => 2015-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 86074 [patent_no_of_claims] => 118 [patent_no_of_ind_claims] => 33 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14808711 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10988904 [patent_doc_number] => 20160185849 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-30 [patent_title] => 'MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING IDIOPATHIC INFLAMMATORY BOWEL DISEASE' [patent_app_type] => utility [patent_app_number] => 14/804164 [patent_app_country] => US [patent_app_date] => 2015-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 44901 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14804164 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11758539 [patent_doc_number] => 20170205408 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-20 [patent_title] => 'Method for Treating Rheumatoid Arthritis' [patent_app_type] => utility [patent_app_number] => 15/326620 [patent_app_country] => US [patent_app_date] => 2015-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 6103 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15326620 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11992494 [patent_doc_number] => 20170296649 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-19 [patent_title] => 'METHOD FOR INDUCING T CELLS FOR CELL-BASED IMMUNOTHERAPY' [patent_app_type] => utility [patent_app_number] => 15/326940 [patent_app_country] => US [patent_app_date] => 2015-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 13766 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15326940 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10548522 [patent_doc_number] => 09273132 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-03-01 [patent_title] => 'Purified antibody composition' [patent_app_type] => utility [patent_app_number] => 14/796779 [patent_app_country] => US [patent_app_date] => 2015-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 9 [patent_no_of_words] => 64144 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 242 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14796779 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11742838 [patent_doc_number] => 20170196910 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-13 [patent_title] => 'GAMMA DELTA T CELLS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/325012 [patent_app_country] => US [patent_app_date] => 2015-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 7639 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15325012 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11671568 [patent_doc_number] => 20170160290 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-08 [patent_title] => 'A NEW BIOMARKER OF CHRONIC ALLOGRAFT NEPHROPATHY AND OF RENAL TRANSPLANT REJECTION' [patent_app_type] => utility [patent_app_number] => 15/323997 [patent_app_country] => US [patent_app_date] => 2015-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 8874 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15323997 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11689646 [patent_doc_number] => 20170165361 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-15 [patent_title] => 'TREATMENT OF LYSOSOMAL DISORDERS (ANTI-TNF THERAPY)' [patent_app_type] => utility [patent_app_number] => 15/325354 [patent_app_country] => US [patent_app_date] => 2015-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 15070 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15325354 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10435875 [patent_doc_number] => 20150320886 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-11-12 [patent_title] => 'COMPOSITIONS AND METHODS FOR DETECTION AND MODULATION OF T CELL MEDIATED IMMUNE RESPONSES AGAINST VIRAL VECTORS UTILIZED FOR GENE THERAPY' [patent_app_type] => utility [patent_app_number] => 14/793007 [patent_app_country] => US [patent_app_date] => 2015-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 7340 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14793007 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11443228 [patent_doc_number] => 20170044249 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-16 [patent_title] => 'MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING TNFalpha-RELATED DISORDERS' [patent_app_type] => utility [patent_app_number] => 14/745092 [patent_app_country] => US [patent_app_date] => 2015-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 48150 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14745092 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10750746 [patent_doc_number] => 20160096897 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-04-07 [patent_title] => 'ANTIBODIES TO MASP-2' [patent_app_type] => utility [patent_app_number] => 14/745247 [patent_app_country] => US [patent_app_date] => 2015-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 18196 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14745247 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10700543 [patent_doc_number] => 20160046691 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-18 [patent_title] => 'Novel Epitope for Switching to TH2 Cell and Use Thereof' [patent_app_type] => utility [patent_app_number] => 14/739763 [patent_app_country] => US [patent_app_date] => 2015-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 14521 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14739763 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10678031 [patent_doc_number] => 20160024177 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-28 [patent_title] => 'Novel Epitope for Switching to TH1 Cell and Use Thereof' [patent_app_type] => utility [patent_app_number] => 14/739770 [patent_app_country] => US [patent_app_date] => 2015-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 35 [patent_no_of_words] => 16158 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14739770 [rel_patent_id] =>[rel_patent_doc_number] =>)